Loading
Overweight and Obesity / Sodium pentaborate pentahydrate · Phase 1/2 Trial
ClinicalTrials.gov · August 11, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a completed phase 1/2 randomized, placebo-controlled trial of sodium pentaborate pentahydrate in 177 people with overweight or obesity. The registry record contains no results, making it impossible to assess safety or efficacy claims at this stage. The trial has finished recruitment, but outcome data have not been posted or published through this registry.
Phase 1/2, Interventional, Randomized, Parallel, Triple masking, Treatment purpose. Overweight and Obesity; age from 18 Years; accepts healthy volunteers. Intervention: Capsules containing sodium pentaborate pentahydrate 200 mg; Capsules containing sodium pentaborate pentahydrate 400 mg; Capsules containing sodium pentaborate pentahydrate 600 mg; Capsules containing sodium pentaborate pentahydrate 800 mg;…. Compared with: Placebo capsules — Placebo Comparator. n = 177. 1 site: Iran.
This is a completed phase 1/2 randomized, placebo-controlled trial of sodium pentaborate pentahydrate in 177 people with overweight or obesity. The registry record contains no results, making it impossible to assess safety or efficacy claims at this stage. The trial has finished recruitment, but outcome data have not been posted or published through this registry.
No efficacy or safety results are reported in this registry record; recruitment completion does not imply data release or publication. Duration of follow-up beyond 12 weeks, adverse event rates, and effect sizes on body weight and glycemic measures are not provided.
This trial cannot yet inform clinical practice because results have not been reported. Once published, outcomes in a small phase 1/2 cohort may inform safety assessment and signal efficacy worthy of larger trials, but would not be sufficient alone to change clinical management.
Phase 1/2 interventional trial with completed enrollment but no results posted in this registry record; design and population are defined but efficacy and safety outcomes remain unreported.
As stated by the source record.
Quoted from the source exactly as published.
This trial cannot yet inform clinical practice because results have not been reported. Once published, outcomes in a small phase 1/2 cohort may inform safety assessment and signal efficacy worthy of larger trials, but would not be sufficient alone to change clinical management.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT05741606). This is a study registration, not published results. Lead sponsor: Tabriz University of Medical Sciences. Recruitment status: COMPLETED. Phase: PHASE1, PHASE2. Study type: INTERVENTIONAL. Enrollment: 177 participants (ACTUAL). Conditions: Overweight and Obesity. Interventions: DRUG: Sodium pentaborate pentahydrate; DRUG: Placebo. Primary outcome measures: Change of body weight , Screening, randomization and weeks 2, 4, 6, 8, 10, 12. Brief summary: This study investigates the safety and efficacy of sodium pentaborate pentahydrate in improving the body weight and glycemic profile of patients with overweight or obesity compared to the placebo group.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.